Implicity Patent Portfolio Analysis

Money arrives long after the filings

Bpifrance, XAnge and Five Arrows Principal Investments put $40.7M into a company founded in 2016 in France. The round is the visible event. The interesting part is what preceded it, and by how long. Implicity's last publicly visible patent filing is dated 17 April 2024, twenty-nine months before this raise. Patent applications publish on a delay, so anything filed since then is still invisible.

That gap is not unusual, but it sets the terms of the assessment. What a reader can see today is a portfolio assembled mostly before the money, not because of it. The claims were written when the company was smaller and the thesis was younger. Whether the round changes the filing pattern is a question the public record cannot answer yet, and will not for some time.

Four in 2021, then a long exhale

Six families since 2021. Four of them landed in that first year, one in 2022, one in 2024. That is a burst followed by a trickle, and bursts like that usually mean a team sitting down once and writing out everything it already knew. The titles point the same way: a transfer device for moving files from a programming device to a remote platform, a system for monitoring health data acquisition devices, a method for predicting how a patient's heart condition will evolve.

Three are granted and enforceable today. Three are published and pending, and the first of those could grant at any time. Filings span AU, CA, US and WO, which is a deliberate geographic spread rather than a home-market reflex. Claims cluster in G16H, healthcare informatics, and A61B, diagnosis and surgery. Ingest, monitor, predict. The portfolio maps to the product with unusual tidiness.

Bursts like that usually mean a team writing out everything it already knew.

One name carries most of the file

Thirteen inventors are named across six families. David Perlmutter appears on four of the six. Arnaud Rosier is on three, Marika Gentils on two. The rest appear once. That shape is common in companies where the technical thesis lives in a small number of heads and the wider team contributes to specific problems as they surface.

It has a consequence worth stating plainly. Concentration like this makes the portfolio legible: you can read four documents and understand what one person thought the hard problem was. It also means the institutional memory of why each claim was drafted the way it was sits with very few people. The hiring plan suggests that is changing. Thirty-three of one hundred open roles are software and AI.

Small circle among very large ones

Over the last five years, the same CPC groups drew Samsung with 1,219 families, Philips with 748, Huawei with 496, Micron with 432, Intel with 408 and Biosense Webster Israel with 388. Implicity has six. On the same scale, the circle is barely a dot. This is not a quiet corner of the art. It is one of the busiest.

Which changes what matters. In an empty field, count is a reasonable proxy for coverage. In a field this dense, count tells you almost nothing and scope tells you everything. Six narrow families in G16H are a rounding error. Six well-drawn ones sitting precisely on remote cardiac data ingestion and prediction are a different object entirely. Even the same-week neighbours in A61B5 are specialists: Covenant, DermaSensor.

In a field this dense, count tells you almost nothing and scope tells you everything.

Five citations, and who made them

The portfolio has been cited by Cardio Intelligence, Medical Ai, Pacesetter, Shandong Science & Tech University and Jinan Lanbo Electronic. One citing publication each. The raw number is small. The composition is not what you would expect from a French startup with six families.

Two of those names are cardiac specialists. One is a device maker. Two are Chinese, one academic and one commercial. Citations of this kind are drawn by examiners and by drafters who found the prior art relevant to what they were claiming. A spread across three countries and four organisation types, off six families, suggests the claims are sitting somewhere that other people working the same problem keep arriving at.

Whether narrow beats numerous here

Here is the position stated plainly. Implicity built its patent estate in a single concentrated effort in 2021, around one dominant inventor, in a technical space occupied by some of the largest filers on earth. Three families are granted and enforceable now. A fourth may join them shortly. The estate is small, geographically deliberate, and precisely aligned with what the company sells: a universal remote cardiac monitoring platform with FDA cleared algorithms.

That is a thin moat that is nonetheless real. Its strength does not come from volume, because volume here is unwinnable. It comes from sitting on a specific claim space that specialists keep citing. The hiring pattern, heavy on software and AI, points toward more of the same claim space rather than a pivot. What the public record cannot yet show is what was filed after April 2024.